[
  {
    "ts": "2025-12-13T15:15:33+00:00",
    "headline": "How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review",
    "summary": "Vertex Pharmaceuticals recently reported clinical data showing that CASGEVY helped all evaluable children aged 5–11 with severe sickle cell disease or transfusion‑dependent beta thalassemia meet key 12‑month endpoints, and it also received a U.S. FDA Commissioner’s National Priority Voucher to speed review for this younger age group. This combination of strong pediatric results and accelerated FDA review could meaningfully expand CASGEVY’s eligible patient pool and reinforce Vertex’s...",
    "url": "https://finance.yahoo.com/news/investors-reacting-vertex-pharmaceuticals-vrtx-151533113.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ad11f1a1-475d-3bcd-b66a-1b69ff0e5559",
      "content": {
        "id": "ad11f1a1-475d-3bcd-b66a-1b69ff0e5559",
        "contentType": "STORY",
        "title": "How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review",
        "description": "",
        "summary": "Vertex Pharmaceuticals recently reported clinical data showing that CASGEVY helped all evaluable children aged 5–11 with severe sickle cell disease or transfusion‑dependent beta thalassemia meet key 12‑month endpoints, and it also received a U.S. FDA Commissioner’s National Priority Voucher to speed review for this younger age group. This combination of strong pediatric results and accelerated FDA review could meaningfully expand CASGEVY’s eligible patient pool and reinforce Vertex’s...",
        "pubDate": "2025-12-13T15:15:33Z",
        "displayTime": "2025-12-13T15:15:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-reacting-vertex-pharmaceuticals-vrtx-151533113.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-reacting-vertex-pharmaceuticals-vrtx-151533113.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]